1MUSIAL A, BAIDA M, MALAWSK A. Recent developments in cholinesterases inhibitors for Alzheimer' s disease treatment[J]. Curr Med Chem,2007 ,14 :2654 - 2679.
3VILLARROYA M, GARCIA A G. MARCO-CONTELLES G J, et al. An update on the pharmacology of galantamine [J]. Expert Pin Investig Drugs, 2007, 16 ( 12 ) : 1987 -1998.
4GARCIA-AYLLON M S, SILVEYRA M X, SAEZVALE- RO J. Association between acetylcholinesterase and β- amyloid peptide in Alzheimer' s cerebrospinal fluid [ J ]. Chemico- B iol Int,2008,175:209 - 215.
5TAKADA-TAKATORI Y, KUME T, IZUMI Y,et al. Roles of nicotinic receptors in acetylcholinesterase inhibitor - induced neuroprotection and nicotinic receptor up-regulation [J]. Biol Pharm Bull, 2009, 32(3) : 318 -324.
6YOO J H, VALDOVINOS M G, WILLIAMS D C. Relevance of donepezil in enhancing learning and memory in special populations : a review of the literature [ J ]. J Autism Dev Disord, 2007,37 : 1883 - 1901.
7Work Group on Alzheimer's disease and other dementias. Am J Psychiatry,2007,164( Suppl, 12) : 1 - 39.
8ONOR M L, TREVISIOL M, AGUGLIA E. Rivastigmine in the treatment of Alzheimer~ disease: an update [ J ]. Clin lnterv Aging,2007,2( 1 ) : 17 - 32.
9RAINA P, SANTAGUIDE P, ISMAILA A,et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia:evidence review for a clinical practice guideline [J]. Ann Int Med, 2008,148:379 -397.
10TISEO P J, PERDOMO C A, FRIEDHOFF L T. ConcuiTent administration of donepezil HC1 and ketoconazole: assessment of pharmacokinetic changes following single and muhiple doses [ J ]. Br J Clin Pharmacol, 1998,46 ( Suppl 1 ) :30 - 34.
